Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.32 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.32 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.31 |
| ▸ | F13A1 | P00488 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557138 | 0.93 | TSHR (0.40) | LMNASLC22A6TSHRKMT2ANFKB1 | |
| SCHEMBL1943663 | 0.93 | TSHR (0.40) | LMNASLC22A6TSHRKMT2ANFKB1 | |
| SCHEMBL1062014 | 0.89 | ALDH1A1 (0.33) | CYP1A2KMT2AMEN1ALDH1A1THRB | |
| Citric Acid SCHEMBL8916871 | 0.83 | ALDH1A1 (0.40) | LMNATSHRKMT2ANFKB1PMP22 | |
| SCHEMBL21986417 | 0.82 | EPHX2 (0.42) | MAPK1SMN1; SMN2LMNATSHRALDH1A1 | |
| SCHEMBL29790176 | 0.82 | KMT2A (0.32) | SMN1; SMN2LMNATSHRKMT2ANFKB1 | |
| SCHEMBL378264 | 0.79 | SCD (0.38) | SMN1; SMN2SLC22A6TSHRKMT2AMEN1 | |
| SCHEMBL3953068 | 0.79 | PTGER3 (0.35) | LMNASLC22A6TSHRKMT2ANFKB1 | |
| SCHEMBL8818958 | 0.79 | FABP4 (0.32) | CYP1A2MAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3719747 | 0.77 | ALDH1A1 (0.34) | TSHRKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739636-B1 | OLIGOSACCHARIDES AND OLIGOSACCHARIDE-PROTEIN CONJUGATES DERIVED FROM CLOSTRIDIUM DIFFICILE POLYSACCARIDE PS-I, METHODS OF SYNTHESIS AND USES THEREOF, IN PARTICULAR AS VACCINES AND DIAGNOSTIC TOOLS | MAX PLANCK GESELLSCHAFT (DE) | 2018-09-26 | — | — | EP | claimed |
| CN-120121612-A | Method for detecting polysaccharide molecular size of multivalent bacterial vaccine | 兰州生物制品研究所有限责任公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | TRIPARTITE THERAPEUTICS INC. (TW) | 2025-01-30 | — | — | US | disclosed |
| US-12187817-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | KODE BIOTECH LIMITED (NZ) | 2025-01-07 | — | — | US | disclosed |
| WO-2024028192-A1 | USE OF CONJUGATES OF HUMAN SERUM ALBUMIN AND PHOSPHOCHOLINE FOR BLOCKING C-REACTIVE PROTEIN | PENTRACOR GMBH (DE) | 2024-02-08 | — | — | WO | disclosed |
| US-20230374076-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | KODE BIOTECH LIMITED (NZ) | 2023-11-23 | — | — | US | disclosed |
| US-11760779-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | KODE BIOTECH LIMITED (NZ) | 2023-09-19 | — | — | US | disclosed |
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-12-02 | — | — | US | disclosed |
| CN-113433122-A | Method for detecting polysaccharide molecular size of bacterial vaccine | 兰州生物制品研究所有限责任公司 | 2021-09-24 | — | — | CN | disclosed |
| US-20210214396-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | KODE BIOTECH LIMITED (NZ) | 2021-07-15 | — | — | US | disclosed |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-03-23 | — | — | US | disclosed |
| WO-2018220603-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | BOVIN NICOLAI VLADIMIROVICH (RU) | 2018-12-06 | — | — | WO | disclosed |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2017060729-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374076-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | SGMS1, SGMS2, CERT1 | CYP1A2 4408/4885MAPK1 4360/4885SMN1; SMN2 294/4885 |
| US-11760779-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | SGMS1, SGMS2, CERT1 | CYP1A2 4370/4885MAPK1 4286/4885SMN1; SMN2 326/4885 |
| US-20210214396-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | SGMS1, SGMS2, CERT1 | CYP1A2 4425/4885MAPK1 4289/4885SMN1; SMN2 274/4885 |
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | CYP1A2 4082/4885MAPK1 2815/4885SMN1; SMN2 3620/4885 |
| US-12187817-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | SGMS1, SGMS2, CERT1 | CYP1A2 4357/4885MAPK1 4299/4885SMN1; SMN2 327/4885 |
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | CD274, SELPLG, PDCD1LG2 | CYP1A2 592/4885MAPK1 2680/4885SMN1; SMN2 3302/4885 |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CD47, MYD88, NFATC1 | CYP1A2 4082/4885MAPK1 2815/4885SMN1; SMN2 3620/4885 |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | CYP1A2 4082/4885MAPK1 2815/4885SMN1; SMN2 3620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.